Distinguishing Partial Lipodystrophy from Cushing’s Syndrome: Clinical Overlaps and Diagnostic Challenges

Highlight

• Partial lipodystrophy (PLD) can closely resemble Cushing’s syndrome (CS) clinically, leading to diagnostic confusion.

• Common validated clinical risk scores for CS lack specificity in distinguishing PLD from actual CS.

• PLD patients often display metabolic complications such as diabetes and hypertriglyceridemia more frequently than CS patients.

• No significant correlation exists between leptin levels and hypothalamic-pituitary-adrenal (HPA) axis hormones in PLD, suggesting complex pathophysiology.

Study Background

Partial lipodystrophies (PLD) are rare disorders characterized by selective loss or redistribution of subcutaneous fat, often coupled with severe metabolic disturbances such as insulin resistance, diabetes mellitus, and dyslipidemia. Clinically, PLD may manifest features that mimic hypercortisolism, notably fat accumulation in specific body regions like the face and dorsocervical area, as well as hirsutism and skin changes. These phenotypic similarities can lead to confusion with Cushing’s syndrome (CS), a condition caused by chronic glucocorticoid excess with distinct clinical and metabolic consequences. Accurate differentiation between PLD and CS is crucial, as management strategies diverge substantially.

Established clinical risk scores have been designed to stratify patients’ probability of having CS by integrating cushingoid features; nevertheless, their performance in patients with PLD is unknown. Furthermore, while animal models suggest that leptin deficiency or resistance, common in lipodystrophies, may modulate the hypothalamic-pituitary-adrenal (HPA) axis, corresponding human data are scant.

Study Design

This retrospective multicenter study included 61 patients diagnosed with partial lipodystrophy and 56 patients with confirmed Cushing’s syndrome. Data were collected from medical records across several specialized centers, encompassing clinical presentations, metabolic profiles, and hormonal investigations.

Two validated clinical risk scores for CS were computed for all patients to evaluate their discriminatory power. Comparative analyses between PLD and CS groups focused on the prevalence of individual clinical features, metabolic abnormalities, and endocrine parameters. Correlations between leptin concentrations and glucocorticoid-related hormonal markers were explored to assess potential leptin-HPA axis interactions.

Key Findings

The study revealed that a majority of PLD patients displayed at least one clinical feature suggestive of hypercortisolism, such as facial fullness, facial plethora, dorsocervical fat pad, and hirsutism. Notably, these signs were statistically more frequent in PLD than in CS (p-values <0.05). Conversely, classical signs of muscle catabolism such as proximal muscle atrophy and osteoporosis were more prevalent in CS patients, emphasizing muscle and bone degradation typical of glucocorticoid excess.

Metabolic complications diverged significantly: PLD patients had markedly higher frequencies of diabetes mellitus and hypertriglyceridemia compared to CS patients (both p < 0.001). These data highlight the profound metabolic derangements inherent to lipodystrophy, beyond the morphological mimicry of CS.

When applying simplified CS clinical risk scores, intriguingly, PLD patients scored equal or even higher than CS patients, reflecting considerable phenotypic overlap. Multivariable regression analysis further elucidated discriminating features: proximal muscle atrophy and osteoporosis correlated strongly with CS, while diabetes and hypertriglyceridemia were independently associated with PLD.

Investigations into hormonal interactions revealed no meaningful correlation between circulating leptin levels and glucocorticoid-related hormones in PLD, suggesting a limited or complex link between leptin status and HPA axis activity in these patients.

Expert Commentary

This study addresses a critical diagnostic challenge by systematically comparing two conditions with overlapping phenotypic features. The findings underscore that cushingoid clinical risk scores lack specificity when applied to patients with partial lipodystrophy, risking misdiagnosis. Clinicians should thus consider lipodystrophy in the differential diagnosis when encountering patients presenting with cushingoid appearance but atypical metabolic profiles.

The dissociation between leptin and HPA axis parameters suggests that leptin’s role in modulating cortisol secretion in humans with PLD may be minimal or influenced by confounding factors such as insulin resistance or adipose tissue distribution. Further prospective studies are warranted to elucidate underlying mechanisms.

Limitations include the retrospective nature of the study and potential center-related selection biases. Nonetheless, the multicenter design and substantial sample size strengthen the generalizability of results across specialized clinical settings.

Conclusion

Partial lipodystrophy can masquerade as Cushing’s syndrome, sharing several morphological and clinical traits that confound straightforward diagnosis. Conventional clinical risk scores for CS should be interpreted with caution in this context. A heightened clinical awareness of the distinctive metabolic profiles and the limitations of clinical scoring tools is essential to avoid misdiagnosis and inappropriate therapies.

Enhanced diagnostic algorithms incorporating metabolic markers and imaging, alongside hormonal assays, may improve differentiation. Awareness of these nuances has direct implications for guiding appropriate endocrinological evaluation, timely diagnosis, and management of these complex disorders.

Funding and Clinical Trial Information

The study details from the original publication did not specify funding sources or clinical trial registry numbers.

References

1. Pigni S, Cecchetti C, Caputo M, et al. Partial Lipodystrophy Mimicking Cushing’s Syndrome: Clinical and Metabolic Insights from a Multicenter Study. J Clin Endocrinol Metab. 2026 Aug 5. PMID: 42554580.

2. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500-4511.

3. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet. 2006;367(9522):1605-1617.

4. Meehan CA, Wroblewski K, Taylor AE, et al. Leptin and the hypothalamic-pituitary-adrenal axis in humans: Impact of leptin deficiency and replacement on cortisol regulation. Eur J Endocrinol. 2005;152(2):211-217.